Dare Bioscience Inc

NASDAQ:DARE  
1.01
0.00 (0.00%)
Products

Daré Bioscience Announces Interim Analysis Of Phase 2B RESPOND Study Of Sildenafil Cream, 3.6%

Published: 08/29/2022 12:18 GMT
Dare Bioscience Inc (DARE) - DarÉ Bioscience Announces Interim Analysis of Phase 2b Respond Study of Sildenafil Cream, 3.6% in Women With Female Sexual Arousal Disorder.
Dare Bioscience Inc- Study Enrollment Expected to Complete in 4q-2022 With Approximately 150 Subjects.
Dare Bioscience Inc- Topline Data of Phase 2b Respond Study Targeted for 2q-2023.